Marimed (MRMD) Gross Margin (2011 - 2026)

Marimed (MRMD) has reported Gross Margin for 16 consecutive years, with 38.7% the latest figure, recorded in Q2 2026.

• On a quarterly basis, Gross Margin fell 162.0% year-over-year to 38.7% in Q2 2026; TTM through Jun 2026 was 35.63%, a 289.0% decrease from a year earlier, with the FY2025 full-year figure at 36.22%, down 349.0% from the prior year.
• Gross Margin was 38.7% for Q2 2026 at Marimed, roughly flat from 38.69% in the prior quarter.
• Over five years, Gross Margin peaked at 54.27% in Q1 2022 and troughed at 25.21% in Q4 2025.
• A 5-year average of 41.72% and a median of 42.61% in 2024 frame the typical range for Gross Margin.
• The widest YoY moves for Gross Margin: up 76 bps in 2022, down 1410 bps in 2022.
• Over 5 years, Gross Margin stood at 44.13% in 2022, then advanced by 1 bps to 44.52% in 2023, then declined by 27 bps to 32.49% in 2024, then slipped by 22 bps to 25.21% in 2025, then surged by 53 bps to 38.7% in 2026.
• The last three Gross Margin figures came in at 38.7% (Q2 2026), 38.69% (Q1 2026), and 25.21% (Q4 2025), per Business Quant data.